Logo image of SCNX

SCIENTURE HOLDINGS INC (SCNX) Stock Fundamental Analysis

NASDAQ:SCNX - Nasdaq - US80880X1046 - Common Stock - Currency: USD

1.58  -0.83 (-34.44%)

After market: 1.55 -0.03 (-1.9%)

Fundamental Rating

3

Taking everything into account, SCNX scores 3 out of 10 in our fundamental rating. SCNX was compared to 38 industry peers in the Health Care Technology industry. No worries on liquidiy or solvency for SCNX as it has an excellent financial health rating, but there are worries on the profitability. SCNX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SCNX has reported negative net income.
SCNX had a negative operating cash flow in the past year.
In the past 5 years SCNX always reported negative net income.
SCNX had negative operating cash flow in 4 of the past 5 years.
SCNX Yearly Net Income VS EBIT VS OCF VS FCFSCNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

The Return On Assets of SCNX (28.09%) is better than 100.00% of its industry peers.
SCNX has a Return On Equity of 35.39%. This is amongst the best in the industry. SCNX outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 28.09%
ROE 35.39%
ROIC N/A
ROA(3y)-109.37%
ROA(5y)-71.82%
ROE(3y)-1295.81%
ROE(5y)-784.69%
ROIC(3y)N/A
ROIC(5y)N/A
SCNX Yearly ROA, ROE, ROICSCNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

SCNX's Profit Margin of 94.17% is amongst the best of the industry. SCNX outperforms 100.00% of its industry peers.
The Operating Margin and Gross Margin are not available for SCNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 94.17%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCNX Yearly Profit, Operating, Gross MarginsSCNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

7

2. Health

2.1 Basic Checks

SCNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCNX has more shares outstanding
The number of shares outstanding for SCNX has been increased compared to 5 years ago.
SCNX has a worse debt/assets ratio than last year.
SCNX Yearly Shares OutstandingSCNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
SCNX Yearly Total Debt VS Total AssetsSCNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -0.50, we must say that SCNX is in the distress zone and has some risk of bankruptcy.
SCNX has a Altman-Z score of -0.50. This is comparable to the rest of the industry: SCNX outperforms 44.74% of its industry peers.
SCNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.5
ROIC/WACCN/A
WACC12.28%
SCNX Yearly LT Debt VS Equity VS FCFSCNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M 6M 8M

2.3 Liquidity

A Current Ratio of 4.18 indicates that SCNX has no problem at all paying its short term obligations.
SCNX has a Current ratio of 4.18. This is amongst the best in the industry. SCNX outperforms 89.47% of its industry peers.
SCNX has a Quick Ratio of 4.18. This indicates that SCNX is financially healthy and has no problem in meeting its short term obligations.
SCNX's Quick ratio of 4.18 is amongst the best of the industry. SCNX outperforms 89.47% of its industry peers.
Industry RankSector Rank
Current Ratio 4.18
Quick Ratio 4.18
SCNX Yearly Current Assets VS Current LiabilitesSCNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.73% over the past year.
The Revenue for SCNX has decreased by -53.03% in the past year. This is quite bad
The Revenue has been growing by 16.65% on average over the past years. This is quite good.
EPS 1Y (TTM)63.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.17%
Revenue 1Y (TTM)-53.03%
Revenue growth 3Y-21.53%
Revenue growth 5Y16.65%
Sales Q2Q%-99.17%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y57.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.1%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SCNX Yearly Revenue VS EstimatesSCNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
SCNX Yearly EPS VS EstimatesSCNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCNX Price Earnings VS Forward Price EarningsSCNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCNX Per share dataSCNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

SCNX has a Yearly Dividend Yield of 601.27%, which is a nice return.
In the last 3 months the price of SCNX has falen by -76.31%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 102.87, SCNX pays a better dividend. On top of this SCNX pays more dividend than 100.00% of the companies listed in the same industry.
SCNX's Dividend Yield is rather good when compared to the S&P500 average which is at 2.33.
Industry RankSector Rank
Dividend Yield 601.27%

5.2 History

SCNX does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
SCNX Yearly Dividends per shareSCNX Yearly Dividends per shareYearly Dividends per share 2024 2 4 6 8

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
SCNX Yearly Income VS Free CF VS DividendSCNX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

More info and screens

SCIENTURE HOLDINGS INC

NASDAQ:SCNX (3/7/2025, 8:00:02 PM)

After market: 1.55 -0.03 (-1.9%)

1.58

-0.83 (-34.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)N/A N/A
Earnings (Next)04-21 2025-04-21/amc
Inst Owners1.85%
Inst Owner Change137.01%
Ins Owners33.22%
Ins Owner ChangeN/A
Market Cap20.81M
Analysts82.86
Price TargetN/A
Short Float %0.45%
Short Ratio1.89
Dividend
Industry RankSector Rank
Dividend Yield 601.27%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-99.59%
Min Revenue beat(2)-100%
Max Revenue beat(2)-99.18%
Revenue beat(4)0
Avg Revenue beat(4)-53.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)-1.66%
Revenue beat(8)1
Avg Revenue beat(8)-31.55%
Revenue beat(12)5
Avg Revenue beat(12)-13.38%
Revenue beat(16)7
Avg Revenue beat(16)-4.94%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.7
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB 1.77
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.34
BVpS0.89
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 28.09%
ROE 35.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 94.17%
GM N/A
FCFM N/A
ROA(3y)-109.37%
ROA(5y)-71.82%
ROE(3y)-1295.81%
ROE(5y)-784.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.18
Quick Ratio 4.18
Altman-Z -0.5
F-Score4
WACC12.28%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.17%
EPS Next Y57.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-53.03%
Revenue growth 3Y-21.53%
Revenue growth 5Y16.65%
Sales Q2Q%-99.17%
Revenue Next Year4.1%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-909.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.13%
OCF growth 3YN/A
OCF growth 5YN/A